

1 **Learnings from the Australian First Few X Household Transmission**

2 **Project for COVID-19**

3

4 Adrian J Marcato¹, Andrew J Black², James Walker^{2,3}, Dylan Morris², Niamh Meagher^{1,4}, David J Price^{1,4}, Jodie

5 McVernon^{1,4,5}, and the Australian FFX Household Transmission Project Group

6

7 ¹ Department of Infectious Diseases, The University of Melbourne, at the Peter Doherty Institute for Infection

8 and Immunity, Melbourne, Australia

9 ² School of Mathematical Sciences, The University of Adelaide, Adelaide, Australia

10 ³ School of Mathematics & Statistics, The University of Melbourne, Melbourne, Australia

11

12 ⁵ Murdoch Children's Research Institute, Melbourne, Australia

13 **Research in context**

14

15 **Evidence before this study**

16 The emergence of SARS-CoV-2 was initially characterised by uncertainty over key epidemiological, clinical
17 and virological characteristics of the pathogen. We conducted a prospective household transmission study of
18 confirmed cases of COVID-19 and their household contacts to collect data to understand severity and household
19 transmission dynamics in Australia and add to the emerging evidence base for decision making. Large
20 systematic reviews and meta-analyses of severity and transmission dynamics of SARS-CoV-2 in households
21 have since been published, although estimates vary by setting.

22

23 **Added value of this study**

24 This is the first multi-jurisdictional prospective household transmission study of its kind for SARS-CoV-2 in
25 Australia. Australia experienced low epidemic activity during the study period in 2020 due to robust public
26 health and social measures including extensive PCR testing of symptomatic persons and isolation of all known
27 contacts of confirmed cases. Hence, we describe the transmission dynamics in our cohort, i.e. in a low incidence
28 setting and provide estimates of the household secondary attack rate, the relative susceptibility of children
29 compared to adults, and transmission from children compared to adults.

30

31 **Implications of all the available evidence**

32 Our findings describe the epidemiology of COVID-19 in Australian households in 2020, and demonstrate the
33 effectiveness of public health measures to limit transmission in this setting. Comparisons to other household
34 transmission studies must be interpreted in light of the local epidemiology and context including study design,
35 and sampling methods. Additional research is needed to incorporate genomic and serological data to further
36 study transmission dynamics in our cohort. Continued development of the FFX study platform in Australia will
37 enable integration into surveillance systems and help inform targetted public health responses to future
38 infectious disease emergencies.

39 **Abstract**

40

41 **Background:**

42 First Few “X” (FFX) studies provide a platform to collect the required epidemiological, clinical and virological
43 data to help address emerging information needs about the COVID-19 pandemic.

44

45 **Methods:**

46 We adapted the WHO FFX protocol for COVID-19 to understand severity and household transmission
47 dynamics in the early stages of the pandemic in Australia. Implementation strategies were developed for
48 participating sites; all household members provided baseline epidemiological data and were followed for 14
49 days from case identification. Household contacts completed symptom diaries and had respiratory swabs taken
50 at baseline, day 7 and day 14, and day 28 where applicable. We modelled the spread of COVID-19 within
51 households using a susceptible-exposed-infectious-recovered-type model, and calculated the household
52 secondary attack rate and key epidemiological parameters.

53

54 **Findings:**

55 96 households with 101 cases and 286 household contacts were recruited into the study between April–October
56 2020. Forty household contacts tested positive for SARS-CoV-2 in the study follow-up period. Our model
57 estimated the household secondary attack rate to be 15% (95% CI 8–25%), which scaled up with increasing
58 household size. Children were less infectious than their adult counterparts but were also more susceptible to
59 infection.

60

61 **Interpretation:**

62 Our study provides important baseline data characterising the transmission of early SARS-CoV-2 strains from
63 children and adults in Australia, against which properties of variants of concern can be benchmarked. We
64 encountered many challenges with respect to logistics, ethics, governance and data management that may have
65 led to biases in our study. Continued efforts to invest in preparedness research will help to test, refine and
66 further develop Australian FFX study protocols in advance of future outbreaks.

67

68 **Funding:**

69 Australian Government Department of Health

70 **Introduction**

71

72 The global spread of the SARS-CoV-2 virus which causes coronavirus disease 2019 (COVID-19) was deemed a
73 pandemic in March 2020.¹ The emergence and global spread of SARS-CoV-2 was initially characterised by
74 uncertainty over key epidemiological, clinical and virological characteristics of the pathogen, particularly, its
75 ability to spread between humans and cause disease in a susceptible population.

76

77 The First Few “X” (FFX) study protocol for COVID-19 published by the World Health Organization (WHO)
78 provides a platform to collect the required epidemiological, clinical and virological data to help address
79 emerging information needs about the pandemic.²⁻⁴ The FFX study protocol is one of several protocols
80 published by WHO as part of their UNITY study framework, which also includes standardised sero-
81 epidemiological study protocols in household, health care and school settings amongst others.^{5,6}

82 In February 2020, the eight Australian state and territory health departments together with the Commonwealth
83 Department of Health and researchers from the Australian Partnership for Preparedness Research on Infectious
84 Disease Emergencies (APPRISE) developed a national plan to implement the WHO FFX study protocol for
85 COVID-19 in Australia.^{7,8} The Australian FFX Household transmission project aimed to inform understanding
86 of local COVID-19 epidemiology in the early epidemic phases, and provide evidence for the development of
87 guidelines and policy in specifically directing Australia’s ongoing public health response. The findings from this
88 investigation are described here.

89 Australia’s first epidemic wave in 2020 was driven by returned international travellers and subsequent local
90 transmission in major urban centres across the country. Public health and social measures were introduced to
91 control the escalating epidemic, which included: border closures, expanded case management and contact
92 tracing, and social measures such as density quotients in workplaces and public venues and lockdowns.

93 Mandatory quarantine for returned international travellers was also introduced to reduce the risk of further
94 importation. These measures drove incident cases in Australia to very low levels, and effective elimination
95 (sustained periods of zero case incidence) was achieved in many states and territories by May 2020. A national
96 strategy was set to pursue no community transmission of COVID-19 in the absence of widespread vaccine
97 coverage.⁹

98 Breaches from the compulsory quarantine system for returned international travellers led to intermittent periods
99 of local transmission in Australia, particularly in 2020 and the early stages of 2021. Australia's second most
100 populous state, Victoria, experienced a second epidemic wave of activity from late May 2020 to November
101 2020.

102 Several Australian states, including New South Wales (Australia's most populous state), Victoria and the
103 Australian Capital Territory now have established community transmission of SARS-CoV-2 due to the delta
104 variant. As of December 13th 2021, there have been 228,930 confirmed cases of COVID-19 in Australia,
105 including 2104 deaths. Of these cases, 220,083 were locally acquired and the majority have been confirmed
106 since June 2021.^{10,11}

107 **Methods**

108 **Study design, ascertainment and eligibility**

109 We adapted the WHO UNITY FFX transmission study protocol for COVID-19, focusing on the household
110 components, with a goal of recruiting 200 households into the project across participating sites.³ Participating
111 sites included New South Wales (NSW; capital Sydney), Victoria (VIC; capital Melbourne), Western Australia
112 (WA; capital Perth), South Australia (SA; capital Adelaide) and Queensland (QLD; capital Brisbane).

113 These adaptations included separating the study into two components: public health (data and viral swab
114 collection as part of enhanced public health unit surveillance activities), and; additional research components
115 (sequencing of positive samples and serology collection and analysis, not presented here), as detailed in
116 Supplementary Table 1.

117 Laboratory confirmed index cases were recruited from the NSW, WA, and QLD state public health units where
118 they were the first case identified in the household according to public health investigations and contact tracing.
119 We recruited co-primary index cases where two household members tested positive within a 24-hour period and
120 there was at least one other household member who was PCR-negative at baseline. In addition, we enriched for
121 index paediatric cases by recruiting from the Royal Children's Hospital Respiratory Infection Clinic (RCH) in
122 VIC. Recruitment was active between April–October 2020, prior to the emergence of any variants of concern
123 (Supplementary Figures 1–4).

124 Households were defined as two or more people living together in a domestic residence or a dwelling or group
125 of dwellings with a shared space. Residential institutions were not included. All locally acquired cases were
126 eligible for recruitment regardless of local source of infection provided they lived within an appropriate
127 geographical area for logistics (i.e., metropolitan areas), and were not in mandated 14-day quarantine. All
128 household members of eligible cases were required to provide their consent to participate. Hospitalised index
129 cases were eligible for recruitment as we assumed that household contacts were exposed by the time
130 hospitalisation of the index case has occurred. Households were excluded when all household members were
131 infected at the time of the initial visit, making the direction of transmission events unclear and unobservable.

132

133 Epidemiological data were collected from confirmed cases and household contacts as close as possible to
134 laboratory confirmation (day 0/baseline) of the index case, including health status interviews on days 7,14 and
135 where available day 28. The questionnaires collected details on participant demographics, symptoms and

136 vaccine and medical history (details provided in Supplementary Table 2). Household contacts also completed
137 daily symptom diaries (via SMS) and provided specimens in line with Public Health Laboratory Network advice
138 at baseline, days 7,14 and where available day 28. Respiratory swabs were professionally or self-collected
139 depending on study site and were tested by polymerase chain reaction (PCR) in the state of collection.¹²
140 Households were cleared from the project at day 14 if all household contacts were symptom free and tested
141 negative for COVID-19 at previous study timepoints (baseline and days 7/14). Index/primary cases did not
142 complete symptom diaries or provide further swabs during their involvement in the study.

143
144 Deidentified data were collected and managed using REDCap electronic data capture tools hosted at The
145 University of Melbourne. Ethics approval was not required for the FFX public health components being led
146 through state and territory health departments as the project was recognised as an enhanced national public
147 health surveillance activity. Ethics approval for the FFX project at the RCH site was obtained through the
148 Murdoch Children’s Research Institute Ethics Committee (ref: 63666).

149

150 **Analysis**

151 Descriptive analyses were performed to explore the characteristics of initially confirmed cases and their
152 household contacts.

153 The household secondary attack rate (HSAR) was defined as the proportion of household contacts that were
154 eventually infected in their study follow-up. We assumed that individuals tested positive for COVID-19 by PCR
155 if and only if they had COVID-19 (i.e., the false positive rate is zero) and infected household contacts had at
156 least one positive PCR test during their follow-up period. We classified all further detected cases within
157 households as secondary cases and assumed that the primary case was the source of infection.

158 We characterised and modelled disease spread within households using an SEIR-type compartmental
159 mathematical model previously developed for pandemic influenza¹³⁻¹⁵, and adapted it for COVID-19 according
160 to early evidence about the incubation period and the generation interval.¹⁶ The model allows for pre- and
161 asymptomatic infection status, and is age-structured allowing for age-specific contact rates.¹⁷ Adults were
162 defined as 18 years old or older, and children were defined as less than 18 years old. The rate of transmission
163 was allowed to scale depending on the household size. Model parameters were estimated using a bespoke
164 Markov chain Monte Carlo method¹⁵⁻¹⁶; additional model details are outlined in the Supplementary Technical
165 Appendix. Median posterior estimates and 95% credible intervals (CrI) are reported.

166

167 Statistical analysis was also conducted to support the choice of variables considered in the mathematical model,
168 identify other variables that may be able to inform the mathematical model, and to align with global FFX and
169 UNITY studies. We used logistic regression models to investigate the association between the HSAR and case-
170 and household-level covariates. Multilevel mixed-effects logistic regression models were used to account for
171 multiple observations per household in the contact-level HSAR analysis. The covariates used in these models
172 are detailed in Supplementary Table 3. Households with co-primary cases were excluded from the statistical
173 HSAR analysis but are included in the household model analysis.

174

175 Alpha was set to 0.05, and covariates that had a p-value of <0.2 in univariate regression analysis were included
176 in the multivariable models for the different variable levels. Adjusted odds ratios, adjusted marginal estimates of
177 the HSAR, and associated 95% confidence intervals (95% CIs) were produced for each included covariate.

178

179 Data cleaning and descriptive analyses were performed in R, (<https://www.r-project.org/>).¹⁸ Statistical HSAR
180 analyses were performed in Stata version 16.0 (StataCorp LLC, College Station, Texas).¹⁹ All modelling and
181 parameter estimation was performed using Julia 1.6.0 (<https://julialang.org/>).²⁰

182 **Results**

183

184 **Characteristics of FFX study population**

185

186 We recruited 96 households with 101 confirmed index cases (due to co-primary cases) and 286 associated
 187 household contacts between April 2020 and October 2020. Three households had a false positive index case and
 188 were subsequently removed. Four households had incomplete study data. Supplementary Figure 1 shows
 189 recruitment into our study over time in relation to the number of locally acquired cases in Australia and in states
 190 that contributed data (Supplementary Figures 2–4).

191

192 FFX cases had a median age of 29 years (Interquartile range 15–42) and there were slightly more female cases
 193 than males. Thirty-five of the confirmed cases were children (<18 years old). Further case and contact
 194 participant characteristics can be seen in Table 1. The median household size was 4 (IQR 3–5) and ranged from
 195 2–10 persons (Supplementary Figure 5).

196

197 **Table 1:** Characteristics of included case and household contact participants in the FFX project

198

	Confirmed cases (n = 101, from 96 households)	Household contacts (n = 286)
Age, years		
Mean (SD)	28·0 (18·3)	28·0 (19·3)
Median (IQR)	29·0 (15·0–42·0)	26·0 (11·0–44·0)
Age group, No. (%)		
<12	21·0 (20·8)	73·0 (25·5)
12–17	14·0 (13·9)	40·0 (14·0)
18–49	55·0 (54·5)	122·0 (42·7)
50+	11·0 (10·9)	51·0 (17·8)
Sex, No. (%)		
Male	48·0 (47·5)	141·0 (49·5)
Female	53·0 (52·5)	144·0 (50·5)
Other	0 (0)	0 (0)
Received influenza vaccination in previous 12 months, No. (%)		
Yes	55·0 (54·5)	131·0 (46·0)
No	45·0 (44·6)	151·0 (53·0)
Unknown	1·0 (1·0)	3·0 (1·0)
Ever had pneumococcal vaccine, No. (%)		
Yes	21·0 (20·8)	82·0 (28·8)
No	62·0 (61·4)	145·0 (50·9)
Unknown	18·0 (17·8)	58·0 (20·4)
Pre-existing health conditions, No. (%)		
Has pre-existing health conditions	27·0 (26·7)	87·0 (30·5)
Has no pre-existing health conditions	74·0 (73·3)	198·0 (69·5)
Asthma	8·0 (7·9)	32·0 (11·2)
Chronic respiratory condition (excluding asthma)	1·0 (1·0)	0 (0)

Cardiac disease	1.0 (1.0)	4.0 (1.4)
Immunosuppressive condition/therapy	0 (0)	1.0 (0.4)
Diabetes	3.0 (3.0)	8.0 (2.8)
Obese	1.0 (1.0)	5.0 (1.8)
Renal disease	1.0 (1.0)	1.0 (0.4)
Other condition(s)	14.0 (13.9)	41.0 (14.4)

199

200 Abbreviations:


201 IQR = Interquartile range

202

203 Household transmission dynamics – mathematical modelling

204

205 Of the 286 household contacts recruited into the study, 40 tested positive for SARS-CoV-2 by PCR, with the
 206 majority (36/40, 90%) being detected and confirmed by the Day 7 timepoint. The modelling analysis is based on
 207 households with sufficient data (92 households comprising of 230 adults and 140 children). Of the included
 208 households, 68 had a single case only and experienced no secondary transmission. Final size distributions (i.e.,
 209 the total number of individuals with laboratory-confirmed infections within a household over the period of
 210 monitoring) are shown in Figure 1.




211

212 **Figure 1:** Final size distributions for the 92 households, where N is the size of the household. A final size of 1
 213 indicates no secondary infections. There are no households of size 9 in the dataset.

214 Posterior distributions for the household secondary attack rate (HSAR) unstratified and stratified by household
 215 size, N (HSAR_N), are shown in Figure 3. In both panels of this figure, HSAR is calculated as an average over
 216 the households in the dataset to account for the age-structured mixing and difference in adult-child

217 transmissibility/susceptibility. The HSAR was estimated to be 15% (95%CrI 8–25%, Figure 2a) which increases
218 with household size (Figure 2b).
219



220


221

222 **Figure 2:** Posterior distributions for (A) the household secondary attack rate (HSAR) and (B) the household
223 secondary attack rate conditional on household size N ($HSAR_N$) shown in blue. The grey curve shows the prior
224 distribution. In (B) the dots represent the median of the distributions. $HSAR$ and $HSAR_N$ are calculated as
225 averages over the households in the study and over all ages.

226

227 Adults had a higher likelihood of showing symptoms than children (Supplementary Figure 8). Children were
228 found to be more susceptible than adults – the median posterior estimate of the relative susceptibility of children
229 compared to adults was 1.26 (95%CrI 0.75–2.08) as seen in Figure 3A. Children were also less infectious than
230 their adult counterparts – the median posterior estimate of relative transmissibility compared to adults was 0.52
231 (95%CrI 0.23–1.06), as seen in Figure 3B.

232



233

234

235 **Figure 3:** Posterior distributions (blue lines) for the relative susceptibility (A) and transmissibility (B) from
236 children compared to adults, shown in blue. Prior distributions are shown in grey.

237

238 **Household transmission dynamics – statistical analysis**

239

240 Using the contact-level mixed-effects logistic regression model and excluding households with co-primary
241 cases, the HSAR estimate was found to be 12% (95% CI 7–17%). Details of the multivariable logistic regression
242 models at the various factor-levels are presented in Supplementary Table 4. The odds ratio estimate for
243 household size was 1.31 (95% CI 0.97–1.77, $p=0.080$), representing an average 31% increase in the odds of
244 secondary infection within the household for each one person increase in household size. There is some
245 evidence to suggest that HSAR is associated with the relationship between cases and their contacts –
246 parents/guardians/carers and siblings had lower odds of being a secondary case when children were the primary
247 case. The other covariates included in the multivariable models were not found to be associated with the HSAR.

248

249 **Severity**

250

251 Four confirmed cases were hospitalised during their follow-up period (Case hospitalisation rate, 2.8% (4/141),
252 95% CI 0.9–7.5%) and no deaths were reported in our cohort.

253

254 Overall, 31.9% (45/141) of confirmed cases were asymptomatic (95% CI 24–40%). 10/101 (9.9%) were
255 asymptomatic primary cases at baseline and 35/40 (87.5%) secondary cases were asymptomatic during their
256 follow-up. Symptoms experienced by household contacts by COVID-19 status can be seen in Supplementary
257 Figure 6.

258

259 Discussion

260

261 Our household transmission study estimates the HSAR in Australia to be 15% (95%CrI 8–25%) prior to the
262 emergence of variants of concern. We demonstrate that the HSAR increases with household size. Children were
263 relatively more susceptible to infection compared to adults when exposed and were also less infectious than
264 their adult counterparts.

265

266 The ‘gold-standard’ mathematical model captures the complex timing and dynamics of transmission in
267 households. Thus, we believe these results to be more robust than those produced by the statistical models.
268 Associations in the statistical modelling need to be taken with caution due to the small sample size and our
269 underlying assumption that all cases we observe in our households are attributed to the primary case – an
270 assumption that is not required in the mathematical model. However, the statistical model results are important
271 as they are broadly consistent with the results from the robust mathematical modelling approach, and represent
272 the standard analytic method that is used to analyse such household transmission studies. They are presented
273 here such that results from our cohort may be fairly compared to other international studies.

274

275 Our HSAR estimate is consistent with estimates from two systematic review and meta-analyses of household
276 transmission.^{21,22} We note that our results differ from similar household transmission studies including studies
277 based on the WHO UNITY protocols, such as the FFX study conducted in the UK, which estimated a higher
278 base HSAR that decreased with increasing household size.²³⁻³³ Other studies using population surveillance data,
279 which represent transmission within a broader range of settings than the household, have estimated lower
280 relative susceptibility to SARS-CoV-2 infection for children compared to adults.^{34,35}

281

282 It can be difficult to make direct comparisons between studies that are conducted in different countries and
283 settings due to the unique features of local epidemics and adaptations required for implementation. Studies
284 should be interpreted in light of the local epidemiology and context – considerations should be made for the
285 surveillance and contact tracing capacity, local incidence of COVID-19 cases during study implementation,
286 predominant circulating SARS-CoV-2 variant, the timing and duration of the study, and study design including
287 case ascertainment strategies and specimen sampling methods. Characteristics of individuals affected by
288 COVID-19 and recruited into the study such as socioeconomic status, occupation and size of recruited
289 households may also be significantly different across these studies, and therefore may influence aggregate

290 outcomes. Additionally, differences in public health interventions such as: test, trace and isolate capacity and
291 practices; behavioural and distancing measures; mobility restrictions; communication campaigns; and varying
292 degrees of community engagement and cohesion in response, could also help to explain how estimates may vary
293 across countries and settings.

294

295 We note ascertainment and recruitment bias in our study cohort that may contribute to some of the differences
296 we observe to other studies – we excluded households where all members of these households were already
297 infected at baseline. This was more likely to exclude smaller households than larger households for
298 participation, and subsequently may have resulted in the HSAR for smaller households being underestimated.
299 Our modelling outputs are therefore influenced more strongly by larger households, particularly three large
300 outbreaks in households with more than five household members. These may be outliers and as such the
301 observed effect could disappear if more data had been collected including from smaller households who
302 experienced rapid transmission making them ineligible for recruitment. Additional sources of data could help us
303 understand the extent to which our results are influenced by our inherent study biases and if our HSAR estimate
304 is an underestimate, or if it is rather a feature of Australia’s unique epidemiology, i.e. transmission in a low
305 incidence setting with stringent public health and social measures to reduce within-household and community
306 transmission.

307

308 We did not observe longer chains of infection in households that had detected secondary transmission. As a
309 result, there were insufficient data to confidently estimate other quantities of interest such as the incubation
310 period, and the pre-symptomatic and symptomatic infectious periods. Although some households experienced
311 larger absolute numbers of cases, in the majority of such households most individuals were already infected at
312 the recruitment baseline or initial swabbing time point (90% of secondary cases were positive by day 7 testing).
313 These outcomes were expected especially as public health units provided extensive advice to reduce the
314 probability of additional spread within the household, including advice on mask use, and how to isolate from
315 each other in their homes. Whilst not the case in this cohort, some cases were removed from their household to
316 further mitigate the risk of spread if their home environment was not suitable for quarantine.

317

318 We conducted sensitivity analyses to consider how the arbitrary age cut-off of 18 years to define adults and
319 children and the use of our contact matrices were impacting our results. We explored age cut-offs of 8,13 and 16
320 years of age. We found that the estimated HSAR was not sensitive to changes in the age cut-off (Supplementary

321 Figure 8). There are small differences in the probability of symptom onset for the different age cut-offs
322 (Supplementary Figure 9), although these appear to be centred on the same values. The age cut-off of 16 yielded
323 posterior estimates for the probability of symptom onset that were very similar. There was no sensitivity to the
324 contact matrix being used – this is likely a result of the large number of households who experienced no
325 secondary transmission.

326

327 Our study has several strengths: This is the first multi-jurisdictional household transmission study of its kind for
328 SARS-CoV-2 in Australia. We provide insights into household transmission with testing of known household
329 contacts regardless of symptoms in a sustained low incidence setting, where there is more certainty about the
330 source of SARS-CoV-2 transmission being from within the household, rather than the community, compared to
331 a higher incidence setting. The pre-existing relationship between public health departments and APPRISE
332 researchers was an enabling factor to provide capacity for the implementation of the study, as Australian health
333 departments were prioritising hospital preparedness and scaling up testing and contact tracing in early 2020
334 when this study commenced. Our study enriched for paediatric cases through recruitment at the RCH site –
335 children were generally not index cases at the other sites, and as such this recruitment strategy provided us with
336 unique insights into household transmission from children in the Australian context.

337

338 Operationally, our data fields were aligned with the National Notifiable Diseases Surveillance Scheme to
339 harmonise with enhanced surveillance efforts and reduce duplication of data collection where possible. Our
340 bespoke REDCap database provided a central repository to analyse FFX data as a national dataset. Analysis and
341 reporting of FFX data was performed in real time to key national and international stakeholders including, the
342 Communicable Diseases Network Australia (CDNA), WHO Headquarters and the WHO Western Pacific
343 Regional Office.

344

345 The lack of an Australian specific protocol with a pre-determined implementation strategy led to issues with
346 logistics, and made it difficult to obtain the relevant ethics and governance approvals for all associated research
347 components. We originally anticipated a 6–8 week window of intense recruitment in line with a short and sharp
348 epidemic in early 2020. Strong social and public health control measures including border closures and
349 mandated hotel quarantine reduced case numbers and subsequently the number of eligible cases and households.
350 Two of our sites (QLD and SA) had sustained zero community transmission of COVID-19 by the time they
351 were ready to recruit in April 2020 and WA achieved this in May 2020 after only recruiting four households.

352 We were able to recruit more as epidemic activity increased in VIC and NSW in mid-2020, but case
353 ascertainment in Victoria was limited due to recruitment being limited to the paediatric hospital site. These
354 factors prolonged the duration of our study and may have further contributed to our ascertainment bias.

355 Future research will also involve further collection and analysis of associated genomic and serological data in
356 the FFX research components to better understand and confirm the transmission dynamics in our cohort.
357 Genomic data can help confirm our classification of individuals as we assumed additional cases in the
358 household were attributed to the index case. Serological data may identify historic infections in individuals who
359 continue to present as PCR positive but are non-infectious. Serological data may also be important to identify
360 previously undetected infections in household members especially as the rate of false negatives from PCR may
361 not be insignificant.³⁶ Together these can provide more accurate data to classify household members and
362 subsequently inform attack rate calculations.

363 Our study provides important baseline data characterising the transmission of early SARS-CoV-2 strains from
364 children and adults in the Australian context, against which properties of emerging variants of concern such as
365 the Alpha and Delta strains can be benchmarked.³⁷⁻⁴⁰ We plan to follow our recruited FFX households
366 longitudinally to continue to develop our understanding of household transmission and immunity in the context
367 of emerging variants of concern. This study will be conducted as Australia's vaccination program continues and
368 throughout the eventual establishment of community transmission of SARS-CoV-2 in Australia. Research is
369 also currently underway to formally evaluate the implementation of our FFX study to help consolidate on
370 lessons learnt and inform preparedness efforts for future FFX studies in Australia for COVID-19 or other
371 infectious disease emergencies.

372

373 **Conclusion**

374

375 The Australian FFX project for COVID-19 has been useful to provide valuable insight into the epidemiology of
376 SARS-CoV-2 in Australia despite encountering many challenges in the planning and implementation phases
377 with respect to logistics, ethics, governance and data management. Continued efforts to invest in preparedness
378 research will help to test, refine and further develop Australian FFX study protocols in advance of future
379 outbreaks of concern and ensure they are embedded in pandemic response plans.^{41,42} Being able to rapidly
380 activate and provide high-quality information in real-time will be useful for epidemic situational assessment and

381 modelling studies in response to future outbreaks of concern, to ensure a more proportionate, equitable and
382 targeted public health response and help reduce disease impact.

383

384 **Funding Sources:**

385

386 The public health components of the Australian FFX Household Transmission Project were funded by the
387 Australian Government Department of Health.

388

389 **Acknowledgements:**

390

391 The Australian FFX Household Transmission Project Group (alphabetical order): Ross Andrews, Laura
392 Bannerman, Christina Bareja, Andrew Black, Douglas Boyle, Georgina Collins, Jo Collins, Loral Courtney,
393 Nigel Crawford, Katina D’Onise, Lucy Deng, Kate Dohle, Andrew Dunn, Paul Effler, James Fielding, Erin
394 Flynn, Rob Hall, Sonia Harmen, Troy Laidlow, Eileen Lam, Adrian Marcato, Jodie McVernon, Niamh
395 Meagher, Adriana Milazzo, Caroline Miller, Dylan Morris, Janette Mulvey, Sera Ngeh, Genevieve O’Neill,
396 Kate Pennington, Priyanka Pillai, Ben Polkinghorne, David Price, Victoria Pye, Joshua Ross, Freya Shearer,
397 Miranda Smith, Paula Spokes, Andrew Steer, Mark Taylor, Shidan Tosif, Florian Vogt, James Walker, Nicholas
398 Wood.

399

400 The Communicable Diseases Network Australia, for their input in the planning stages of the project, oversight
401 and review of the article.

402

403 **References:**

- 404 1 World Health Organization. WHO Director-General's opening remarks at the media briefing on
405 COVID-19 - 11 March 2020 [Internet]; 2020 ([https://www.who.int/director-](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)
406 [general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)
407 [11-march-2020](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020), accessed 6th December 2021)
408
- 409 2 World Health Organization, Global Research on coronavirus disease (COVID-19); 2021
410 ([https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov)
411 [coronavirus-2019-ncov](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov) , accessed 6th December 2021)
412
- 413 3 World Health Organization, The first few X cases and contacts (FFX) investigation protocol for
414 coronavirus disease 2019 (COVID-19), version 2.2; 2021 ([https://www.who.int/publications/i/item/the-](https://www.who.int/publications/i/item/the-first-few-x-cases-and-contacts-(ffx)-investigation-protocol-for-coronavirus-disease-2019-(covid-19)-version-2.2)
415 [first-few-x-cases-and-contacts-\(ffx\)-investigation-protocol-for-coronavirus-disease-2019-\(covid-19\)-](https://www.who.int/publications/i/item/the-first-few-x-cases-and-contacts-(ffx)-investigation-protocol-for-coronavirus-disease-2019-(covid-19)-version-2.2)
416 [version-2.2](https://www.who.int/publications/i/item/the-first-few-x-cases-and-contacts-(ffx)-investigation-protocol-for-coronavirus-disease-2019-(covid-19)-version-2.2) , accessed 6th December 2021)
417
- 418 4 Marcato AJ, Fielding J, Crooks K et al. The ongoing value of First Few X studies for COVID-19 in the
419 Western Pacific Region. In press article.
420
- 421 5 World Health Organization, Coronavirus disease (COVID-19) technical guidance: The Unity Studies:
422 Early Investigation Protocols; 2021 ([https://www.who.int/emergencies/diseases/novel-coronavirus-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/early-investigations)
423 [2019/technical-guidance/early-investigations](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/early-investigations) , accessed 6th December 2021)
424
- 425 6 Bergeri I, Lewis HC, Subissi L et al. Early epidemiological investigations: World Health Organization
426 UNITY protocols provide a standardized and timely international investigation framework during the
427 COVID-19 pandemic. *Influenza Other Respir Viruses*. 2021 [Epub ahead of print].
428 doi:10.1111/irv.12915 pmid:34611986
429
- 430 7 The Australian Partnership for Preparedness Research on Infectious Disease emergencies, 2021 (
431 <https://www.apprise.org.au/> , accessed 6th December 2021)
432

- 433 8 The Australian Partnership for Preparedness Research on Infectious Disease emergencies. First Few X'
434 (FFX) research project to enhance the public health response to COVID-19 in Australia. 2021,
435 ([https://www.apprise.org.au/project/first-few-x-ffx-research-project-to-enhance-the-public-health-](https://www.apprise.org.au/project/first-few-x-ffx-research-project-to-enhance-the-public-health-response-to-covid-19-in-australia/)
436 [response-to-covid-19-in-australia/](https://www.apprise.org.au/project/first-few-x-ffx-research-project-to-enhance-the-public-health-response-to-covid-19-in-australia/) , accessed 6th December 2021)
437
- 438 9 Australian Government Department of Health, Australian Health Protection Principal Committee
439 (AHPPC) statement on strategic direction, 2020; ([https://www.health.gov.au/news/australian-health-](https://www.health.gov.au/news/australian-health-protection-principal-committee-ahppc-statement-on-strategic-direction)
440 [protection-principal-committee-ahppc-statement-on-strategic-direction](https://www.health.gov.au/news/australian-health-protection-principal-committee-ahppc-statement-on-strategic-direction), accessed 6th December 2021)
441
- 442 10 Australian Government Department of Health, Coronavirus (COVID-19) current situation and case
443 numbers, 2021; [https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-](https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/coronavirus-covid-19-current-situation-and-case-numbers)
444 [alert/coronavirus-covid-19-current-situation-and-case-numbers](https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/coronavirus-covid-19-current-situation-and-case-numbers) , accessed 6th December 2021)
445
- 446 11 COVID-19 National Incident Room Surveillance Team (2021). COVID-19 Australia: Epidemiology
447 Report 55 Reporting period ending 21 November 2021. *Communicable diseases intelligence*
448 (2018), 45, 10.33321/cdi.2021.45.65. <https://doi.org/10.33321/cdi.2021.45.65>
449
- 450 12 Australian Government Department of Health, Public Health Laboratory Network Publications, 2021
451 (<https://www1.health.gov.au/internet/main/publishing.nsf/Content/Publications-13> , accessed 6th
452 December 2021)
453
- 454 13 Black AJ, Geard N, McCaw JM, McVernon J, Ross JV. Characterising pandemic severity and
455 transmissibility from data collected during first few hundred studies. *Epidemics*. 2017;19:61-73.
456
- 457 14 Black, AJ. Importance sampling for partially observed temporal epidemic models. *Statistics and*
458 *Computing*, 2019, 29, 617-630
459
- 460 15 Walker JN, Black AJ, Ross JV. Bayesian model discrimination for partially-observed epidemic models.
461 *Math Biosci*. 2019;317:108266.
462

- 463 16 Lauer SA, Grantz KH, Bi Q et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19)
464 From Publicly Reported Confirmed Cases: Estimation and Application. *Ann Intern Med.*
465 2020;172(9):577-82.
466
- 467 17 Prem K, Cook AR, Jit M. Projecting social contact matrices in 152 countries using contact surveys and
468 demographic data. *PLOS Computational Biology.* 2017;13(9):e1005697.
469
- 470 18 R Core Team (2021). R: A language and environment for statistical computing. R Foundation for
471 Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>
472
- 473 19 StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC.
474
- 475 20 Julia: A Fresh Approach to Numerical Computing. Jeff Bezanson, Alan Edelman, Stefan Karpinski,
476 Viral B. Shah. (2017) *SIAM Review*, 59: 65–98. doi: 10.1137/141000671.pdf.
477
- 478 21 Madewell ZJ, Yang Y, Longini IM, Jr, Halloran ME, Dean NE. Household Transmission of SARS-
479 CoV-2: A Systematic Review and Meta-analysis. *JAMA Network Open.* 2020;3(12):e2031756-e.
480
- 481 22 Thompson HA, Mousa A, Dighe A et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
482 CoV-2) Setting-specific Transmission Rates: A Systematic Review and Meta-analysis. *Clinical*
483 *Infectious Diseases.* 2021;73(3):e754-e64.
484
- 485 23 House T, Pellis L, Pouwels KB et al., Inferring Risks of Coronavirus Transmission from Community
486 Household Data. Preprint. arXiv. 2021; <https://arxiv.org/abs/2104.04605>
487
- 488 24 Dattner I, Goldberg Y, Katriel G et al. The role of children in the spread of COVID-19: Using
489 household data from Bnei Brak, Israel, to estimate the relative susceptibility and infectivity of children.
490 *PLOS Computational Biology.* 2021;17(2):e1008559.
491

- 492 25 Li F, Li Y-Y, Liu M-J et al. Household transmission of SARS-CoV-2 and risk factors for susceptibility
493 and infectivity in Wuhan: a retrospective observational study. *The Lancet Infectious Diseases*.
494 2021;21(5):617-28.
495
- 496 26 Pung R, Park M, Cook AR, Lee VJ. Age-related risk of household transmission of COVID-19 in
497 Singapore. *Influenza Other Respir Viruses*. 2021;15(2):206-8.
498
- 499 27 Reukers DFM, van Boven M, Meijer A, et al. High infection secondary attack rates of SARS-CoV-2 in
500 Dutch households revealed by dense sampling. *Clinical Infectious Diseases*. 2021.
501
- 502 28 Cerami C, Popkin-Hall ZR, Rapp T et al. Household transmission of SARS-CoV-2 in the United
503 States: living density, viral load, and disproportionate impact on communities of color. *Clin Infect Dis*.
504 2021.
505
- 506 29 Lewis NM, Chu VT, Ye D et al. Household Transmission of SARS-CoV-2 in the United States. *Clin*
507 *Infect Dis*. 2020.
508
- 509 30 Ng OT, Marimuthu K, Koh V et al. SARS-CoV-2 seroprevalence and transmission risk factors among
510 high-risk close contacts: a retrospective cohort study. *The Lancet Infectious Diseases*. 2021;21(3):333-
511 43.
512
- 513 31 Ratovoson R, Razafimahatratra R, Randriamanantsoa L et al. Household transmission of COVID-19
514 among the earliest cases in Antananarivo, Madagascar. *Influenza Other Respir Viruses*. 2021.
515
- 516 32 Bernal JL, Panagiotopoulos N, Byers C et al. Transmission dynamics of COVID-19 in household and
517 community settings in the United Kingdom. *medRxiv*. 2020:2020.08.19.20177188.
518
- 519 33 Miller E, Waight PA, Andrews NJ et al. Transmission of SARS-CoV-2 in the household setting: A
520 prospective cohort study in children and adults in England. *J Infect*. 2021.
521

- 522 34 Viner RM, Mytton OT, Bonell C et al. Susceptibility to SARS-CoV-2 Infection Among Children and
523 Adolescents Compared With Adults: A Systematic Review and Meta-analysis. *JAMA Pediatrics*.
524 2021;175(2):143-56.
525
- 526 35 Davies NG, Klepac P, Liu Y et al. Age-dependent effects in the transmission and control of COVID-19
527 epidemics. *Nature Medicine*. 2020;26(8):1205-11.
528
- 529 36 Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in False-Negative Rate of
530 Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure.
531 *Ann Intern Med*. 2020;173(4):262-7.
532
- 533 37 Davies NG, Abbott S, Barnard RC et al. Estimated transmissibility and impact of SARS-CoV-2 lineage
534 B.1.1.7 in England. *Science*. 2021;372(6538):eabg3055.
535
- 536 38 Wibmer CK, Ayres F, Hermanus T et al. SARS-CoV-2 501Y.V2 escapes neutralization by South
537 African COVID-19 donor plasma. *bioRxiv*. 2021:2021.01.18.427166.
538
- 539 39 Naveca F, Nascimento V, Souza V et al. COVID-19 epidemic in the Brazilian state of Amazonas was
540 driven by long-term persistence of endemic SARS-CoV-2 lineages and the recent emergence of the
541 new Variant of Concern P.1, 25 February 2021, PREPRINT (Version 1) available at Research Square
542 [<https://doi.org/10.21203/rs.3.rs-275494/v1>
543
- 544 40 Public Health England, SARS-CoV-2 variants of concern and variants under investigation in England,
545 Technical briefing 11; 2021 ([https://www.gov.uk/government/publications/investigation-of-novel-sars-
546 cov-2-variant-variant-of-concern-20201201](https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201), accessed 6th December 2021)
547
- 548 41 Australian Health Sector Emergency Response Plan for Novel Coronavirus (COVID-19) ; 2020
549 ([https://www.health.gov.au/resources/publications/australian-health-sector-emergency-response-plan-
550 for-novel-coronavirus-covid-19](https://www.health.gov.au/resources/publications/australian-health-sector-emergency-response-plan-for-novel-coronavirus-covid-19) , accessed 6th December 2021)
551

552 42 Australian Government Department of Health. Australian Health Management Plan for Pandemic
553 Influenza; 2014 (<https://www1.health.gov.au/internet/main/publishing.nsf/Content/ohp-ahmppti.htm> ,
554 accessed 6th December 2021)
555

556 **Supplementary Appendix**

	Summary	Funding source
<i>Public health component</i>	<ul style="list-style-type: none"> - Data collection from confirmed cases as close as possible to laboratory confirmation including status interviews on days 7,14 ± 28 - Data collection from household contacts including daily symptom diaries and status interviews on days 7,14, ± 28 - Specimens at days 0,7,14 ± 28 from household contacts. Professionally collected or self-collected depending on site, in line with the Australian Public Health Laboratory Network advice - Households to end participation where the entire household is symptom and COVID-19 free at the day 14 time point 	Australian Commonwealth Department of Health
<i>Research component 1 – components of protocol not deemed to be essential public health activity in February 2020</i>	<ul style="list-style-type: none"> - Sequencing of previously collected positive specimens in the public health project - Collection of blood sample from household contacts after any self-isolation/quarantine periods have been served 	APPRISE Centre of Research Excellence
<i>Research component 2 – extended follow-up of FFX cohort over 3 year period</i>	<ul style="list-style-type: none"> - Repeat serology from current recruits - Ongoing FFX recruitment – trialling FluTracking arm and Aboriginal Community Controlled Health Organisation led First Nations pilot study 	Australian National Health and Medical Research Council (partnership grant in collaboration with the Australian Commonwealth Department of Health and Hunter New England Local Health District)

557 **Supplementary Table 1:** Australian FFX Household Transmission Project Components and details

558

559 **Supplementary Table 2:** Data collected in the Australian FFX questionnaires

Case data	Contact data
<ul style="list-style-type: none"> - Demographic data; age, sex, pregnancy - Aboriginal and Torres Strait Islander status - Household demographics; household size and number of bedrooms, postcode - Symptom data (including symptom diaries where relevant) - Comorbidity data - Laboratory data (swabs) - Influenza/pneumococcal vaccination data - Follow up data; including hospitalisation status at study time points 	<ul style="list-style-type: none"> - Demographic data; age, sex, pregnancy - Aboriginal and Torres Strait Islander status - Relationship to case, and extent of contact - Symptom data (including symptom diaries) - Comorbidity data - Laboratory data (swabs) - Influenza/pneumococcal vaccination data - Follow up data; including hospitalisation status at study time points

560

561

562 **Supplementary Table 3:** Covariates explored in the univariate and multivariable logistic and negative binomial
 563 regression models
 564

Case covariates	<ul style="list-style-type: none"> - Number of respiratory symptoms experienced by the case (fever, cough, sore throat, shortness of breath, loss of taste, loss of smell, runny nose) - Does the case have conditions that may affect ability to transmit onwards or not (asthma, chronic respiratory disease, immunosuppression) - Time between date of symptom onset and date of baseline test as a proxy for time before PHU intervention - Gender of primary case - Hospitalisation of the case
Household covariates	<ul style="list-style-type: none"> - Household size (for direct comparison to the mathematical model) - Household density – proxy calculated as HH size divided by the number of bedrooms in the household - Composition of household – family (parent/s and children), share-house, complex (multigenerational family or other) - Number of children (<18 years) in household
Contact covariates	<ul style="list-style-type: none"> - Gender of contacts - Relationship to case - Number of measured contact events at baseline (include sharing of spaces, facilities, bedroom) - Time between the case baseline test and first contact test as a proxy for time before PHU intervention - Number of pre-existing conditions (asthma, chronic respiratory condition, cardiac disease, immunosuppressive condition/therapy, diabetes, obesity, liver disease, renal disease, neurological disorder)

565

566

567 **Supplementary Table 4:** Results from the multivariable logistic regression models of HSAR. Covariates were
 568 included in the multivariable logistic regression models if they had a p-value of <0.2 in univariate regression
 569 analysis. The estimates presented here are exclusive of households with co-primary cases.

570

Covariate	Variable level	Adjusted odds ratio (95% CI)	p-value	Adjusted HSAR estimate (95% CI)
<i>Household-level model (n=91)</i>				
<i>Household size[#]</i>	2	Overall – 1.35 (0.99, 1.84)*	0.054*	0.11 (0.02, 0.21)*
	3			0.15 (0.07, 0.24)*
	4			0.20 (0.11, 0.28)*
	5			0.26 (0.15, 0.35)*
	6			0.33 (0.16, 0.46)*
	7			0.41 (0.16, 0.60)*
	8			0.49 (0.15, 0.75)*
	9			0.57 (0.15, 0.90)*
	10			0.65 (0.24, 0.96)*

<i>Case-level model (n=91)</i>				
<i>Ever hospitalised (from case-level model)</i>	No	Ref		0.21 (0.13, 0.30)
	Yes	2.56 (0.29, 22.34)	0.395	0.40 (0, 0.90)
<i>Number of transmitting conditions (asthma, chronic respiratory disease, immunosuppression)</i>	0	Ref		0.20 (0.11, 0.29)
	1	2.75 (0.61, 12.34)	0.186	0.40 (0.07, 0.74)
<i>Contact-level model (n=276)</i>				
<i>Multilevel mix effects logistic regression model, incorporating clustering by household</i>				
<i>Contact relationship to case</i>	Child	Ref	-	0.22 (0.10, 0.33)
	Other***	0.60 (0.01, 4.14)	0.271	0.08 (0, 0.23)
	Parent/guardian/carer	0.07 (0.01, 0.39)	<0.01	0.04 (0, 0.09)
	Partner/spouse	0.57 (0.15, 2.24)	0.422	0.16 (0.06, 0.27)
	Sibling	0.23 (0.04, 1.16)	0.074	0.1 (0.01, 0.17)
<i>Sex</i>	Female	Ref	-	0.10 (0.04, 0.14)
	Male	2.37 (0.80, 6.95)	0.117	0.14 (0.08, 0.20)
<i>Number of pre-existing conditions (as defined in Supplementary Table 3)</i>	0	Ref	-	0.10 (0.05, 0.14)
	1	6.37 (1.40, 28.89)	0.016	0.26 (0.10, 0.39)
	2	2.47 (0.10, 62.85)	0.585	0.16 (0, 0.42)

571

572 * Results from the univariate regression models are presented where only one covariate was eligible to be

573 included in the multivariable model


574 *** Includes grandparents, grandchildren, partners of household contacts, housemates

575 # HH sizes were fit as a continuous variable and estimates presented for the range of household sizes in our study

576 population. We didn't have a household of size 9, and so we are extrapolating from the data that we have

577

578




579

580 **Supplementary Figure 1:** Recruitment into the Australian FFX project (bars) and confirmed cases across
581 Australia (line). Note that the epidemic curve represents includes all cases reported in Australia from the
582 commencement of the project (April 6th 2020), and not necessarily all eligible local cases for inclusion into the
583 project.

584

585



586

587 **Supplementary Figure 2:** Recruitment into the Australian FFX project (bars) and confirmed cases in New
 588 South Wales (line). Note that the epidemic curve represents includes all cases reported in New South Wales
 589 from the commencement of the project (April 6th 2020), and not necessarily all eligible local cases for inclusion
 590 into the project.

591

592

593

594

595

596

597


598

599

600

601

602



603

604 **Supplementary Figure 3:** Recruitment into the Australian FFX project (bars) and confirmed cases in Victoria
605 (line). Note that the epidemic curve represents includes all cases reported in Victoria from the commencement
606 of the project (April 6th 2020), and not necessarily all eligible local cases for inclusion into the project identified
607 at the Royal Children’s Hospital.

608

609


610

611

612

613

614



615

616 **Supplementary Figure 4:** Recruitment into the Australian FFX project (bars) and confirmed cases at the
 617 Western Australia (line). Note that the epidemic curve represents includes all cases reported in Western
 618 Australia from the commencement of the project (April 6th 2020), and not necessarily all eligible local cases for
 619 inclusion into the project.

620

621

622

623

624

625

626


627

628

629


630

631




632

633 **Supplementary Figure 5:** Histogram of recruited household sizes by state.



634

635 **Supplementary Figure 6:** Symptoms reported by household contacts during study follow-up.



636

637

638 **Supplementary Figure 7:** Prior distribution on the generation time implied by the prior distributions on the
639 basic parameters discussed in the Supplementary Technical Appendix. The solid line represents the mean and
640 the shaded region the 95% Credible Intervals.

641

642

643

644

645


646

647

648


649

650



651 **Supplementary Figure 8:** Posterior distributions for the household secondary attack rate using different age
652 cut-offs to define children and adults (in years).

653



654

655

656

657 **Supplementary Figure 9:** Posterior distributions for the probability of displaying symptoms, conditional on

658 testing positive for adults (blue) and children (green) defined at various age cut-offs (in years). The grey curve

659 indicates the prior distribution.

660

661 **Additional model details – modelling appendix**

662

663 Disease spread within a household was characterised using an SEIR-type compartmental mathematical model

664 previously developed for pandemic influenza¹⁻³, adapted to COVID-19. The model allows for pre- and

665 asymptomatic infection status, and is age-structured with age-specific contact rates.⁴ Adults were defined as 18

666 years old or older, and children were defined as less than 18 years old.

667

668 The structure of the model is illustrated in Appendix Figure 1 with associated parameters described in Appendix

669 Table 1. The classes are split into multiple, identical stages, which makes the distribution of time spent within

670 each class Erlang distributed (rather than exponential) to more accurately reflect the distribution time in each

671 period. The number of stages was chosen to reflect evidence about the distributions of the incubation period


672 and/or the generation interval.⁵

673

674 The rate of transmission scales depending on the household size, N , and the ages of individuals that they make
 675 contact within a household. The transmission rate from an infectious adult of age n to a susceptible adult of age
 676 m is given by
 677

$$\frac{\beta c_{n,m}}{(N-1)^\alpha}$$

678
 679 where parameters are as described in Appendix Table 1. The infection rate is scaled based on an individual's age
 680 – specifically, the rate of transmission from an adult to a child is multiplied by r_s , the rate of transmission from a
 681 child to an adult is multiplied by r_t , and the rate of transmission from a child to another child is multiplied by
 682 $r_s r_t$. The terms r_s and r_t represent the relative susceptibility and transmissibility of children, respectively.



683
 684
 685 **Appendix Figure 1:** SEIR model structure for the spread of COVID-19 within a household. This illustrates the
 686 epidemiological states an individual may be in and how they transition between these states. These states are: S
 687 (susceptible); $E_{1,2,3}$ (exposed); $P_{1,2,3}$ (pre-symptomatic and infectious); $I_{1,2}$ (infectious and symptomatic); $I_{1a,2a}$
 688 (infectious and asymptomatic), and; R (recovered). The red arrow indicates the transition when an individual
 689 begins to show symptoms. At some point within the infectious period an individual may be hospitalised, and
 690 hence removed from the household.

691
 692 **Appendix Table 1:** Parameters for the model shown in Appendix Figure 1.

693

Parameter	Description
N	Size of household
$c_{n,m}$	Contact rate between age n and m individuals
$1/\sigma$	Average time spent in exposed states
$1/\lambda$	Average time spent in pre-symptomatic states
$1/\gamma$	Average time spent in states I_1, I_2, I_{1a} and I_{2a}
p_a	Probability of developing symptoms for adults
p_c	Probability of developing symptoms for children
β	Rate of infection from adults to adults per contact in a

	household of size 2
r_s	Relative susceptibility of children
r_t	Relative transmission from children
α	Household size transmission scaling term

694

695 Bayesian inference is performed targeting the parameters of the model using a custom Markov chain Monte
 696 Carlo method. The likelihood is estimated using a particle filter that targets the final size of the outbreak within
 697 a house, thus we ignore temporal information such as the timing of tests and symptom onset. This approach is
 698 adopted as there is very little temporal information and what is available is poorly resolved.

699

700 Prior distributions for all parameters of the model are given below:

$$\begin{aligned}
 R_0 = \beta(\lambda^{-1} + \gamma^{-1}) &\sim \text{Gamma}(5, 1/3) \\
 \sigma^{-1} &\sim \text{N}(5 \cdot 56 - \lambda^{-1}, 0 \cdot 41^2) \\
 \lambda^{-1} &\sim \text{U}(0, 2) \\
 \gamma^{-1} - 1 &\sim \text{Gamma}(5, 3/5) \\
 r_s &\sim \text{Gamma}(5, 1/7) \\
 r_t &\sim \text{Gamma}(10, 1/9) \\
 p_a &\sim \text{Beta}(4, 8/3) \\
 p_c &\sim \text{Beta}(4, 8/3) \\
 \alpha &\sim \text{N}(1/2, 1/4), \text{truncated to } (-1.5, 1.5)
 \end{aligned}$$

701

702

703 The model priors for the average latent period and pre-symptomatic infectious periods (σ^{-1} and λ^{-1}) were fitted
 704 using data on exposure windows and symptom onset times from Lauer et al. (2020).⁵ This distribution is
 705 calculated using a particle marginal Metropolis Hastings method assuming a uniform [0,10] prior on $1/\sigma$ (the
 706 average exposed period), a uniform [0,10] prior on $1/\lambda$ (the average pre-symptomatic infectious period) and
 707 discrete uniform (1,15) shape parameters for each distribution. The resulting joint distribution on σ^{-1} and
 708 λ^{-1} was found to be well approximated by the parametric combination given above.

709

710 The prior for the average infectious period γ^{-1} was chosen with a mode of 3-4 days and a mean of 4 days. The
 711 key quantity which arises from these temporal parameters is the generation time. The distribution for this was
 712 obtained by sampling from the joint prior of the parameters ($R_0, \sigma^{-1}, \lambda^{-1}, \gamma^{-1}$) and using simulation of the full
 713 compartmental model in a fully susceptible population. The final size depends on the transmissibility and
 714 generation time distribution, and the effective prior for the generation time distribution is shown in
 715 Supplementary Figure 7.⁶ This is consistent with the distribution reported in *Ferretti et. al (2020)*.⁷

716 Prior distributions were set on the relative susceptibility, r_s and transmissibility, r_t such that the prior
717 distribution for r_s had mode 0.5 and the prior distribution for r_t has mode 1. Each of these distributions are
718 relatively uninformative which captures the prior uncertainty in the parameter values surrounding the
719 differences between children and adults in relation to transmission. The prior distribution on both the
720 observation probabilities was centered around 0.6. The prior distribution on the effect of household size, α was
721 taken to be a Normal distribution with mean 0.5 and variance 0.25 truncated on the interval (-1.5, 1.5). This
722 facilitates the possibility of density dependent transmission when $\alpha = 0$ and frequency dependent transmission
723 when $\alpha = 1$.

724 **References for supplementary information**

- 725 1 Black AJ, Geard N, McCaw JM, McVernon J, Ross JV. Characterising pandemic severity and
726 transmissibility from data collected during first few hundred studies. *Epidemics*. 2017;19:61-73.
727
- 728 2 Black, AJ. Importance sampling for partially observed temporal epidemic models. *Statistics and*
729 *Computing*, 2019, 29, 617-630
730
- 731 3 Walker JN, Black AJ, Ross JV. Bayesian model discrimination for partially-observed epidemic models.
732 *Math Biosci*. 2019;317:108266.
- 733 4 Prem K, Cook AR, Jit M. Projecting social contact matrices in 152 countries using contact surveys and
734 demographic data. *PLOS Computational Biology*. 2017;13(9):e1005697.
735
- 736 5 Lauer SA, Grantz KH, Bi Q et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19)
737 From Publicly Reported Confirmed Cases: Estimation and Application. *Ann Intern Med*.
738 2020;172(9):577-82.
739
- 740 6 Ball F. A Unified Approach to the Distribution of Total Size and Total Area under the Trajectory of
741 Infectives in Epidemic Models. *Advances in Applied Probability*. 1986;18(2):289-310
742
743
- 744 7 Ferretti L, Wymant C, Kendall M et al. Quantifying SARS-CoV-2 transmission suggests epidemic
745 control with digital contact tracing. *Science*. 2020;368(6491):eabb6936.